Clinical Trial Update: A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial assessing INC280 in combination with gefitinib for EGFR-mutated, c-MET-amplified non-small cell lung cancer after progression on EGFR inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• INC280

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08